期刊文献+

RP-HPLC法测定琥珀酸曲格列汀的有关物质及酸降解杂质的LC-MS/MS分析 被引量:3

Determination of related substances in trelagliptin succinate by RP-HPLC and identification of impurities from acid degradation by LC-MS/MS
原文传递
导出
摘要 目的:建立高效液相色谱法测定曲格列汀的有关物质,并对酸降解产生的主要杂质进行了结构推证。方法:采用sepax C18色谱柱(250 mm×4.6 mm,5μm);流动相A为0.05 mol·L^-1乙酸铵缓冲盐,流动相B为乙腈,梯度洗脱;检测波长为230 nm;流速为1 m L·min^- 1;柱温30℃;曲格列汀样品进样量为20μL。ESI电离源,负离子模式。结果:在该条件下曲格列汀和各有关物质峰分离良好;琥珀酸曲格列汀在0.001-2 mg·m L^-1浓度范围内(r=0.999 9,n=6),浓度和峰面积呈良好的线性关系;本法的定量限(S/N=9)为0.3μg;检测限(S/N=3)为0.1μg;解析出酸破坏后主要增加杂质结构为2-[(3-甲基-2,4,6-三氧代四氢嘧啶-1(2H)基)-甲基]-4-氟苯甲腈。结论:本方法简便、准确、灵敏、可靠,能有效测定琥珀酸曲格列汀中有关物质的含量。 Objective: To establish an HPLC method for the determination of related substances in trelagliptin succinate,and identify the main impurities from acid degradation. Methods: The separation was performed on a sepax C18column( 250 mm × 4. 6 mm,5 μm). Mobile phase A was 0. 05 mol·L^-1ammonium acetate buffer solution,and mobile phase B was acetonitrile. Gradient elution was performed at a flow rate of 1. 0 m L·min^- 1. The detection wavelength was 230 nm. The column temperature was maintained at 30 ℃. The injection volume was20 μL. The ionization source was ESI,and negative ion mode was used for detection. Results: Trelagliptin succinate was completely separated from related substances; the linear range of the method was 0. 001 ~ 2 mg·m L^-1with a correlation coefficient of 0. 999 9. The limit of detection was 0. 1 μg. The limit of quantitation was 0. 3 μg. The structure of the acid destroyed product was 2-[( 3-methyl-2,4,6-oxo-tetrahydro-pyrimidin-1( 2H) yl)-methyl]-4-fluorobenzonitrile. Conclusion: This method is simple,sensitive,selective and reliable,and can be used for the determination of related substances of trelagliptin succinate.
出处 《中国新药杂志》 CAS CSCD 北大核心 2016年第2期226-231,共6页 Chinese Journal of New Drugs
关键词 琥珀酸曲格列汀 有关物质 梯度洗脱 LC-MS/MS trelagliptin succinate related substances gradient elution LC-MS/MS
  • 相关文献

参考文献11

二级参考文献210

  • 1杜伟奇,施秀芳,邱明艳,张文博.治疗糖尿病药物的研究进展[J].中国医院药学杂志,2005,25(1):70-72. 被引量:25
  • 2丁虹伶,程训民,骆合德,冯金忠.二甲双胍对老年2型糖尿病患者的疗效及安全性[J].东南国防医药,2005,7(2):112-113. 被引量:11
  • 3李永强,冯志强,宋宏锐,郭彦伸,郭宗儒.葡萄糖激酶及其小分子活化剂研究进展[J].药学学报,2006,41(5):390-394. 被引量:9
  • 4夏玲红.治疗糖尿病的新药西他列汀[J].中国新药杂志,2007,16(12):979-981. 被引量:26
  • 5Green BD, Flan PR, Bailey Cj. Dipeptidyl peptidase Ⅳ ( DPP Ⅳ) inhibitors:A newly emerging drug class for the treatment of type 2 diabetes. Diab Vasc Dis Res. 2006,3 ( 3 ) : 159. 被引量:1
  • 6Rosenstock J, Brazg R, Andryuk PJ. Efficacy and safety of the dipeptidyl peptidase -4 inhibitor sitagliptin added to ongoing pioglitazone therapy in patients with type 2 diabetes : a 24 - week, multicenter, randomized, double - blind, placebo - controlled, parallel - group study. Clin Ther. 2006,28 (10) : 1556. 被引量:1
  • 7Sitagliptin with metformin : profile of a combination for the treatment of type 2 diabetes. Drugs Today(Barc). 2007,43 (10) :681. 被引量:1
  • 8Raz I, Chen Y, Wu M, et al. Efficacy and safety of sitagliptin added to ongoing metformin therapy in patients with type 2 diabetes. Curr Med Res Opin. 2008,24(2) :537. 被引量:1
  • 9Mistry GC, Bergman A J, Luo WL, et al. Multiple -dose administration of sitagliptin, a dipeptidyl peptidase - 4 inhibitor, does not alter the single - dose pharmacokinetics of rosiglitazone in healthy subjects. Diabetes Obes Metab. 2007,47 ( 2 ) : 159. 被引量:1
  • 10Brazg R, Xu L, Dalla man C, et al. Effect of adding sitagliptin, a dipeptidyl peptidase- 4 inhibitor, to metformin on 24 -h glycemic control and beta - cell function in patients with type 2 diabetes. Rapid Commun Mass Spectrom. 2007,9 (2) :186. 被引量:1

共引文献70

同被引文献16

引证文献3

二级引证文献7

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部